Teeth Whitening Products Market Research Report and Global Industry Analysis

The global Teeth Whitening Products Market is expected to reach USD 7.40 billion by 2024. The industry is driven by the mounting consumer demand for clean and white teeth coupled with awareness about oral hygiene. Moreover, 99.2% of the people believe that smile is an important social benefit and growing consumer preference for over the counter products in countries such as Germany, France, UK, India and China are anticipated to drive the growth of the market over the forecast period.

The leading teeth whitening products manufacturing companies are focusing on R&D to enhance its product portfolio and are expanding their presence in the global market by acquiring local players of that region. For instance, in April 2017, Colgate-Palmolive acquired Ciba-Geigy, an India-based teeth whitening brand, to expand its reach towards the rural parts of India. These factors are expected to provide an impetus to the growth of the market over the next coming years.

Browse Details of Report @

https://www.hexaresearch.com/research-report/teeth-whitening-products-market

Whitening toothpaste segment holds the largest share in the market in terms of revenue and is expected to maintain its position over the forecast period. Whitening toothpaste has a major role in oral hygiene maintenance. Unhealthy lifestyle accompanied by consumption of liquor, cola, tobacco and other related products which cause discoloration of the teeth are anticipated to drive the market globally.

The whitening strips segment was valued at USD 899.8 million in 2016 and are likely to witness a significant growth as a result of rising consumer demand and the requirement for quick result formulas. Furthermore, initiatives and campaigns have taken up by leading companies such as Colgate-Palmolive, P&G and GlaxoSmithKline to create awareness among consumers to use herbal products for teeth whitening are expected to augment the growth of the market.

The increase of these market is determined mainly by consumer demand which is to be favoured by the rising living standards such as modernization, personality traits and appearance. There is a huge competition in the teeth whitening products market as the market is consolidated. The leading players are acquiring the major local players and expanding its production capacity and presence globally. The leading manufacturers in these markets are Colgate-Palmolive, Proctor & Gamble, GlaxoSmithKline, Johnson & Johnson, Unilever and Henkel.

Hexa Research has segmented the global teeth whitening products market based on type and region:

Segmentation by type, 2014 - 2024 (USD Million)

• Whitening Toothpaste

• Whitening Stripes & gels

• Others

Segmentation by region, 2014 - 2024 (USD Million)

• North America

    • U.S.

• Europe

    • Germany

    • UK

• Asia Pacific

    • China

    • India

• Central & South America

• Middle East and Africa

Key players analyzed

• Colgate-Palmolive

• GlaxoSmithKline

• Johnson & Johnson

• Proctor & Gamble

• Unilever

• Church & Dwight

• Brodie & Stone

• CCA Industries

• GO SMILE

• Henkel

Browse Related Category Market Reports @

https://www.hexaresearch.com/research-category/healthcare-industry

U.S. Medical Cannabis Market is Expected to Witness Substantial Growth till 2024

The U.S. Medical Cannabis Market is expected to be valued at USD 19.48 billion by 2024, driven by its numerous medical benefits particularly by patients suffering from cancer, chronic pain and diabetes. Favorable regulatory environment across numerous states including California and Colorado is expected to fuel the growth of the market over the next few years.

Medical Marijuana Regulation and Safety Act implemented in 2015 permits the cultivation and use of cannabis dispensaries at the state and local level which has been one of key drivers to fuel the U.S market. The rising number of states receiving approval to utilize cannabis for consumption in medical cases is expected to be one of the crucial factors to upsurge the demand for medical marijuana over the forecast period.

Browse Details of Report @ https://www.hexaresearch.com/research-report/us-medical-cannabis-market

Over the past few decades, there have been several controversies surrounding legalization of cannabis for medical purposes; however, increasing signs of medical benefits received from the consumption of cannabis has resulted in the herb being legalized across various states in the nation. The industry is expected to witness significant growth during the forecast period owing to greater consumer acceptance along with an increasing number of companies entering the market.

The symptoms and conditions that can be treated by the herb include cancer, arthritis, epilepsy, nausea, pain Alzheimer’s disease, anorexia, AIDS, HIV, glaucoma, cachexia, Crohn’s disease, migraines, and multiple sclerosis. Chronic pain accounted for 46% of the U.S. cannabis medical market share in 2016. The ability of medical marijuana to curb pain is expected to gain popularity among patients diagnosed with chronic illnesses and pain.

In 2016, solid edibles segment dominated the U.S market generating revenues worth USD 2.47 billion and is expected to continue dominating the industry over the forecast period. The future product innovation and potential growth are substantial owing to continuous development from the consumption of cannabis infused products owing to their numerous applications including lotions, bath salts, shampoo, lip balm, toothpaste, coffee pods, baked brownies cookies, candy, confectioneries, beverages, vinegar and oils.

California is known to be the first state in U.S. that legalized cannabis for medical purpose. In 2016, California recorded the highest revenue generation and is expected to grow at a CAGR of 13% over the projected period. Over the next few years, more number of state governments are expected to legalize cannabis owing to its numerous benefits which will fuel its growth over the projected period.

Hexa Research has segmented the U.S. medical cannabis market based on usage, consumption and state:

Segmentation by usage, 2014 - 2024 (USD Million)

• Chronic Pain

• Arthritis

• Migraine

• Cancer

• Others

Segmentation by consumption, 2014 - 2024 (USD Million)

• Solid Edibles

• Inhalation

• Liquid Edibles

• Topical

Segmentation by state, 2014 - 2024 (USD Million)

• California

• Colorado

• Washington

• Arizona

• Michigan

Key players analyzed

• American Cannabis

• Canopy Growth Corporation

• Greengro Technologies

• Medical Marijuana Inc.

• United Cannabis

• Terra Tech Corp.

• Mentor Capital, Inc

• Cannabis Sativa, Inc.

• GBSciences, Inc.

• The Green Solution

Browse Related Category Market Reports @
https://www.hexaresearch.com/research-category/healthcare-industry

Global Biosimilars Market is Expected to Reach USD 13.1 Billion by 2024

             

The Global Biosimilars Market is expected to reach USD 13.1 billion by 2024 on account of increase in the prevalence of chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases. Rising demand for the cost-effective therapies is expected to drive the market in the forecast period. Biosimilars are about 30% cheaper than their counterpart biologics. Furthermore, the patent expiry of the blockbuster drugs is anticipated to provide a lucrative opportunity for the growth of biosimilars. For instance, a patent for Bevacizumab, sold under the trade name Avastin is expiring in 2019.

Moreover, increasing government initiatives, speedy drug approvals and reimbursement policies are expected to boost the market for the biosimilars in the study period. Also, market giants are adopting merger & acquisition strategies to increase their product portfolio. For instance, in 2015, Pfizer, Inc. acquired Hospira, a key player in biosimilars market.

Browse Details of Report @ https://www.hexaresearch.com/research-report/biosimilars-market

In 2016, oncology was the largest segment, accounting for 32% market share. Increasing prevalence of cancer across the globe is the key factor driving the growth of the market over the forecast period. For instance, according to the American Cancer Society, an estimated 1.6 lakh people suffered from cancer in 2016. Also, increasing government initiatives to provide cost effective treatment to cure deadly diseases will boost the penetration of biosimilar in developing countries which in turn will increase the market for biosimilar over the forecast period. For instance, WHO launched a pilot program for prequalifying biosimilar drug, making some of the most expensive treatments for cancer more widely available in developing countries. Under this initiative, WHO has focused on two essential drug rituximab (principally used for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia), and trastuzumab (for the treatment of breast cancer).

In terms of region, Europe dominates the market for biosimilars followed by North America. The dominance of Europe is due speedy approval of the drug by European regulatory bodies. Furthermore, improving healthcare infrastructure and ageing population is expected to drive the market over the forecast period. However, Asia Pacific is projected to be the fastest growing region owing to the increasing disposable income of middle-class families, growing medical tourism and improving healthcare infrastructure. Furthermore, increasing investment in R&D activities by pharmaceutical giants is expected to boost the market in the projected period.

Hexa Research has segmented the global biosimilars market based on indication and region:

Segmentation by indication, 2014 - 2024 (USD Million)
• Blood Disorders
• Oncology
• Chronic & Autoimmune Diseases
• Others

Segmentation by region, 2014 - 2024 (USD Million)
• North America
    • U.S.
• Europe
    • Germany
• Asia Pacific
    • China
    • India
    • Japan
• Rest of the world

Key players analyzed:
• Dr. Reddy’s Laboratories Ltd
• Mylan
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• Pfizer Inc.
• Sandoz International GmbH
• Teva Pharmaceuticals Industries Ltd.
• Amgen Inc.
• STADA Arzneimittel AG
• Biocon
• F. Hoffmann-La Roche Ltd.

Browse Related Category Market Reports@ https://www.hexaresearch.com/research-category/healthcare-industry

Visceral Pain Market is Expected to Witness Substantial Growth due to Increasing Geriatric Population Globally

The Global Visceral Pain Market is expected to reach USD 14.22 billion by 2024, driven by the increasing geriatric population globally. Increasing prevalence of visceral pain and rising awareness regarding the same is projected to drive market growth over the forecast period.

In 2016, North America held the majority of share in global visceral pain market owing to the increasing healthcare expenditure. Additionally, the high prevalence of Crohn’s and irritable bowel is expected to propel the growth of the market over the projected period.

Asia Pacific is expected to be the fastest growing region with the CAGR of 6.2%. The increase in the healthcare infrastructure and presence of a large pool of patients is projected to drive the demand for the visceral pain industry during the forecast period.

Analgesic segment dominated the market for the visceral pain with the market share of 60.4%. The major share of the analgesic segment is attributed to the increasing penetration of generic drug. Furthermore, rising healthcare expenditure and an increasing use of opioids for the chronic pain are the key factors attributing to its share.

In 2016, Crohn’s disease was the largest indication segment for the visceral pain market contributing to 41.4% of the market share. Increasing occurrences of Crohn’s disease across the globe coupled with the growing drug therapies for the treatment of the disease are the key factors attributing to the major share. Furthermore, increasing awareness about Crohn’s disease is fueling the demand for treatment therapies.

Key market players include Pfizer, Johnson & Johnson, Abbvie, Takeda, Allergan, and AstraZeneca. These companies are focusing on R&D for visceral pain therapeutics. These companies are likely to cater their products to patients affected by visceral pain. The growth of the geriatric population is expected to help in augmenting the profits of these companies over the next few years.

Growing focus on research and development by pharmaceutical companies and government initiatives are expected to boost the visceral pain industry during the forecast period. The market is projected to witness significant gain during the forecast period owing to increasing collaboration within pharmaceutical companies. Also, factors such as increasing awareness among people regarding visceral pain are further anticipated to propel the market growth.

Browse Details of Report @https://www.hexaresearch.com/research-report/visceral-pain-market  

Hexa Research has segmented the global visceral pain market on the basis of therapeutics, indications and region:

Segmentation by therapeutics, 2014 - 2024 (USD Million)

• Analgesics

    • Narcotics

    • NSAID

• Pain modifiers

    • Tricyclic Antidepressants

    • Tricyclic Anticonvulsant

• Others

Segmentation by indications, 2014 - 2024 (USD Million)

• Interstitial cystitis

• Crohn’s

• Irritable bowel

• Chronic prostatitis

Segmentation by region, 2014 - 2024 (USD Million)

• North America

• Europe

• Asia Pacific

• Rest of the World (RoW)

Key players analyzed:

• Pfizer Inc.

• Allergan

• Johnson & Johnson

• Bayer AG

• Takeda Pharmaceutical Company Limited

• Mallinkrodt Pharmaceuticals

• AbbVie Inc.

• AstraZeneca

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/clinical-diagnostics-industry

Bioinformatics Market Analysis, Size, Share, Growth and Forecast to 2020 - Hexa Research

The global Bioinformatics Market is projected to expand at a CAGR over 21% during the forecast period (2014 to 2020). In revenue terms, the industry could reach nearly USD 14 billion by 2020. It is propelled by growing demand for advanced drugs and prevalence of chronic diseases. Application of information technology for the effective management of biological information is known as bioinformatics.

Affordable costs of DNA sequencing and strong support from private sector organizations & governments are factors that positively impact the global industry. Furthermore, steady developments in IT support for bioinformatics systems may fuel market demand in the forthcoming years. A number of research institutes focus greatly on discovering & developing novel drugs in the area of life sciences. Widespread adoption of bioinformatics in clinical diagnostics is a vital industry driver.

Browse details of Report @ https://www.hexaresearch.com/research-report/bioinformatics-industry

The global bioinformatics market is segmented on the basis of sectors, products & services, applications, and regions. Based on sectors, the industry is divided into environment biotechnology, animal biotechnology, forensic biotechnology, agriculture biotechnology, academics, forensic biotechnology, and medical biotechnology. The forensic biotechnology segment is a rapidly growing one because of high demand for DNA evidence in legal systems.

The sub-segments of medical biotechnology are reproductive biotechnology, clinical diagnostics, drug development, gene therapy, and molecular medicines. Owing to high sunk costs, medical biotechnology holds the highest share in the overall market in terms of revenue. According to products & services, the worldwide industry is categorized into bioinformatics services, bioinformatics platform, and bioinformatics knowledge management tools. Bioinformatics tools are further segmented into generalized knowledge management tools and specialized knowledge management tools. Bioinformatics platforms include sequence alignment platforms, sequence analysis platforms, functional & structural analysis platforms, and sequence manipulation platforms.

Bioinformatics services are classified into database management, sequencing service, data analysis, and others. Data analysis and database management are by far the most expensive because of these need human intervention for interpretation and technology for data organization. On the basis of applications, the global Bioinformatics Market is divided into molecular phylogenetics, proteomics, metabolomics, chemo informatics & drug design, transcriptomics, and others. Genomics is anticipated to be the largest market by 2020. And metabolomics may register the highest growth rate during the forecast period.

The regional segments of the global Bioinformatics Market are Asia Pacific, North America, Europe, and Rest of the World. North America dominated the overall industry in 2014 owing to technological developments and continuous efforts towards drug discovery & development. The region may retain its leading position throughout the forecast period. Asia Pacific may expand at a remarkable rate because of medical tourism, high investments in healthcare IT, and greater CRO activities. Brazil, China, and India could create significant growth prospects in the forthcoming years.

Prominent companies operating in the global industry are Life Technology Corporation, Biomax Informatics AG, CLC Bio, Id Business Solutions, and Nonlinear Dynamics Ltd. In order to understand & block the progression of cancer, researchers have identified certain proteins that get altered in different types of cancers. When these are targeted with drugs that block their activities, the progression of cancer can be halted to an extent. Researchers & scientists from the University of Cambridge and from Hungary utilized databases of genes that are involved in cancer.

It was observed that cancer related proteins are strongly connected to the main protein networks. Some of the key proteins in the networks have the capacity to facilitate changes that convert healthy cells into cancer cells. The cancer proteins do not interact directly with another but through their surrounding first neighbors. The concerned researchers have successfully utilized computational methods to identify the exact proteins that need to be targeted by drugs.

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/healthcare-it-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit Our Blog - https://hexaresearchinc.wordpress.com/

Sevoflurane, Isoflurane and Desflurane Market Analysis, Size and Forecast to 2022 - Hexa Research

The Sevoflurane, Isoflurane and Desflurane Market is expected to reach USD 1.5 billion by 2022 in comparison to USD 1.2 billion in 2014. These three chemicals are inhalation agents and have been used by anesthesiologists, nurse anesthetists, and anesthesiology assistants on a consistent basis. They are very strong and cost less, with minimum damage to the ozone layer.  

Market Drivers

One of the primary factors, triggering expansion in the sevoflurane, isoflurane and desflurane market includes cardiovascular and respiratory diseases affecting the geriatric population. Rising cancer, orthopedic, spinal and gastro-intestinal cases have also furthered the market. Cataract surgery is a major contributor to the global market and will need a higher production of these chemicals.

Growing accidents and emergency cases also add income to the inhalation anesthesia market. Universal insurance coverage as well as constant improvements in medical infrastructure also ensure the development of the sevoflurane, isoflurane and desflurane market. These agents are administered to patients prior surgery, making the induction of general anesthesia much simpler.

A major factor hindering the market is the quantity of CO₂ released in the environment,   leading to global warming. Actually, only about 5 percent of the gases are consumed by patients. The rest are released into the atmosphere and make it unhealthy. The most practical solution for this problem is the anesthetic recycling of products used during the administration of general anesthesia.

Browse Details of Report@

https://www.hexaresearch.com/research-report/sevoflurane-isoflurane-desflurane-industry

Products Overview

Sevoflurane

Sevoflurane is one of the most commonly used volatile anesthetic agents. It is administered to babies and children. Sevoflurane is ideal for patients with asthma or sensitive air passages. But its side-effects include delirium and agitation. It can be given quickly without the use of intravenous instruments.

Sevoflurane would capture over 70% of the worldwide sevoflurane, isoflurane and desflurane market by 2022. The agent is expected to exceed USD 1 billion by the same year. It’s widely utilized for being low-priced and possessing therapeutic benefits.

Isoflurane

Isoflurane is a halogen ether utilized frequently by veterinarians. It is administered intravenously, relaxes the muscles and reduces pain. Isoflurane has also been used for inducing sleepiness for long durations during surgery. It is expected to register a CAGR of about 10% by 2022.

Desflurane

Desflurane is a halogen ether used in general anesthesia. Its effectiveness is one-fifth of isoflurane. Desflurane cannot be administered orally and requires an electrically heated dispenser to distribute the vapor. It is mostly administered to bariatric patients and in cases of surgeries lasting for short durations.

Regional Overview

The United States has a large geriatric population. This has led the region of North America to occupy the biggest share in the worldwide inhalation anesthesia market in 2014. Surgical ambulatory and inpatient procedures are the driving factors of North America.

Asia Pacific will experience the fastest growth by 2022. This is owing to the rise of chronic diseases and need for better health infrastructure in the region. Medical tourism combined with insurance coverage will play a huge role in sustaining the growth of the sevoflurane, isoflurane and desflurane market.

Key Players

The market is currently dominated by AbbVie and Baxter International. However, it can   expect strong competition from manufacturers like Lunan Pharmaceutical Group and Piramal Enterprises.

Piramal Enterprises currently has isoflurane and sevoflurane production underway. It will manufacture generic desflurane by 2016. AbbVie has sevoflurane and isoflurane under production. Baxter International is the only one that manufactures all the three products.

Anesthesia has some unhealthy effects. The recycling companies of Deltasorb Technologies and Anesthetic Gas Reclamation reprocess anesthesia containers and gases from hospital vents. Rising investments by the aforementioned players would also accelerate the sales of the sevoflurane, isoflurane and desflurane market.

Browse Related Category Market Reports@

https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit Our Blog - https://hexaresearchinc.wordpress.com/

Global Polio Vaccines Market Size, Share | Industry Report, 2021 | Hexa Research

Polio vaccines are the vaccines that are employed to avert the rates of poliomyelitis. Two kinds of polio vaccines are available. The first one deploys inactivated poliovirus and is offered via injection and the other one utilizes weakened poliovirus which is offered through mouth. It has been found that it is quite secure to use the inactivated polio vaccines. At times what happens, at the site of injection, mild redness or pain occurs.

On the contrary, the oral polio vaccines lead to vaccine-associated paralytic poliomyelitis in about three per million doses. It has been observed that the chances for a person to get paralyze after a polio infection are quite few. However, both are generally considered as safe to give at the time of pregnancy and to those who have HIV/AIDS. Recommendations by World Health Organization states that all the children around the world should be vaccinated against polio.

It is said that these two categories of vaccines have contributed largely in eradicating polio from majority of the parts in the world that has in turn decreased the number of cases. Market size on the basis of application spans Pediatric, and Adult. Among both of them, the pediatrics segment is likely to obtain the largest share in the market, the reason being increase in the number of awareness programs for raising awareness regarding vaccination.

Browse Details of Report @ https://www.hexaresearch.com/research-report/polio-vaccines-market

Market size on the basis of geography spans North America, China, Europe, Japan, India, and Southeast Asia. As far as the geography is concerned, North American is currently leading the market, the reason being initiatives laid down by the government for encouraging the adoption of immunization against diseases like influenza and HPV.

Target Audience of the global polio vaccines market include Vaccine Manufacturers, Clinical Laboratories, Vaccine Associations, Vaccine Research Institutes, Group Purchasing Organizations (GPOs), Vaccine Raw Material Suppliers, Immunization Centers, Research and Consulting Firms, Vaccine Product Distributors, Vaccine Development Institutes and Organizations, Hospitals and Laboratories, and Biotechnology and Biopharmaceutical Companies. Major companies operating in the global polio vaccines market include Emergent BioSolutions, Inc, Astellas Pharma Inc, CSL Limited, GlaxoSmithKline, Johnson & Johnson, MedImmune, LLC, Merck & Co, Pfizer, Sanofi Pasteur, and Serum Institute India Pvt. Ltd.

Browse Related Category Market Reports @
https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit Our Blog - hexaresearch1.blogspot.com